Elan Strikes $1 Billion Royalty Deal With Theravance
Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline for its respiratory drugs.
The Irish drugmaker last month rejected a $5.7 billion bid from Royalty Pharma and has made a series of moves to counter the bid, contingent on 90 percent acceptance, since the U.S. investment firm declared its interest in February.
The latest move sees Elan spend some of the $2 billion it has at its disposal following the sale to U.S. firm Biogen Idec of its 50 percent share in multiple sclerosis drug Tysabri. Elan has maintained royalty rights of up to 25 percent in Tysabri, which Royalty Pharma wants to get its hands on.
Elan's Chief Executive Kelly Martin denied that Monday's deal was designed to frustrate the Royalty bid.
"This (Theravance deal) was not done because of Royalty whatsoever. Royalty to myself, to the board, to pretty much every shareholder that we can talk to frankly is utterly irrelevant," Martin told Reuters in a telephone interview. "I can say unequivocally that I haven't spoken to one shareholder who thinks Royalty Pharma's offer is either credible or of any substance whatsoever. We haven't talked to anybody that is on the fence."
The Theravance deal, part of which will be financed by an imminent bond deal, hands Elan a chunk of Theravance's interest in four drugs in late-stage development, including Breo, a new chronic obstructive pulmonary disease (COPD) treatment that was approved by the U.S. Food and Drug Administration on Friday.
Anoro, a potentially more profitable COPD drug Theravance is developing with Britain's Glaxo, is also part of the deal along with another experimental drug awaiting approval, Vilanterol VI, and MABA '081, which has completed phase II trials.
The approval of Breo, which will compete with Glaxo's twice-daily asthma and COPD drug Advair, a roughly $8 billion-a-year drug, means the deal will be earnings' accretive for Elan from next year, the Dublin-based company said.
COPD, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both, is the third-leading cause of death in the U.S., according to federal data. Glaxo has 44 percent of the 22 billion respiratory market.
Theravance, in which Glaxo has a 27 percent shareholding, has separate royalty agreements in place for each molecule. It will receive 15 percent of the first $3 billion sales of Breo and up to 10 percent of Anoro, if is approved.
Analysts expect Breo, or Relvar as it would be called if approved outside the U.S., to generate annual sales of $559 million by 2015, according to Thomson Reuters data. Anoro is expected to generate peak annual sales of nearly $1.4 billion.
Elan said it would pass on one-fifth of all royalties from the Theravance deal to its shareholders, matching the dividend they are already set to receive through the royalty stream Elan maintains in Tysabri following its $3.25 billion sale to former U.S. partner Biogen Idec.
Elan shareholders, whom the company have already rewarded through a $1 billion share buyback, have until May 31 to make up their minds on Royalty Pharma's $11.25 per share bid and Martin reiterated that more deals would be done in the near term.
"We have other transactions that we'll do that will have us involved more directly with other assets and those assets could give us footprint geographically, could give us pipeline and mid-to-late stage assets, or a combination of both," he said.
"We're not just a royalty company alone but what this transaction does is it unbelievably diversifies us, gives us long-term income and will allow us to use that to invest in different assets, molecules or businesses etc."